Ocugen (OCGN) Operating Income (2014 - 2026)
Ocugen (OCGN) reported Operating Income of -$17.8 million for Q1 2026, down 23.02% on a YoY basis from -$23.2 million in Q1 2025, and down 4.97% quarter-over-quarter from -$17.0 million in Q4 2025.
Ocugen (OCGN) Operating Income (2014 - 2026) Analysis & Trends
Ocugen has reported Operating Income for 13 years, with the latest figure at -$17.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 23.02% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$66.3 million (down 16.15% YoY), and the FY2025 full-year result was -$62.9 million, down 14.9% from the prior year.
- Operating Income for Q1 2026 stood at -$17.8 million, down from -$17.0 million in the prior quarter.
- The five-year high for Operating Income was -$11.5 million in Q4 2023, with the low at -$25.1 million in Q3 2022.
- Historically, Operating Income has averaged -$17.1 million across 5 years, with a median of -$17.0 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Income slumped 169.66% — and 2023, when it surged 50.65%.
- Ocugen's Operating Income stood at -$23.4 million in 2022, then soared by 50.65% to -$11.5 million in 2023, then declined by 20.09% to -$13.8 million in 2024, then decreased by 22.8% to -$17.0 million in 2025, then slipped by 4.97% to -$17.8 million in 2026.
- The last three Operating Income figures came in at -$17.8 million (Q1 2026), -$17.0 million (Q4 2025), and -$17.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -17.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -17.63 Mn |
| Jun 30, 2025 | -13.80 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Sep 30, 2024 | -13.25 Mn |
| Jun 30, 2024 | -15.45 Mn |
| Mar 31, 2024 | -12.22 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -23.36 Mn |
| Sep 30, 2022 | -25.11 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.57 Mn |
| Sep 30, 2021 | -10.79 Mn |
| Jun 30, 2021 | -25.61 Mn |